Dr. Reddy's gets OK to market generic allergy drug

HYDERABAD, India — A federal court has lifted an injunction that had prevented drug maker Dr. Reddy’s Labs from marketing a generic version of an allergy drug.

Dr. Reddy’s said the U.S. District Court of New Jersey had filed a stipulation and order lifting the earlier injunction against the drug maker regarding the selling of a version of fexofenadine hydrochloride and pseudoephedrine hydrochloride tablets in the 180-mg/240-mg strength. The drug is a generic version of Sanofi-Aventis’ and Albany Molecular Research’s Allegra-D 24.

Sanofi and Albany Molecular Research had filed suit against Dr. Reddy’s, alleging patent infringement. In June 2010, the court granted the two companies an injunction preventing Dr. Reddy’s from selling its version of the drug.